About us

Originating from pioneering research at Bonn University Hospital, bradyMX is pioneering the next generation of early Parkinson’s detection through a tablet-based diagnostic platform that identifies subtle motor biomarkers years before traditional diagnosis.

Initial trials have demonstrated the feasibility of this approach, successfully distinguishing prodromal patients from healthy controls using initial algorithms.

Building on this foundation, the team is now training advanced models on expanded datasets that capture hand motion, facial expression, speech, and gait patterns – all measured using standard tablet sensors. The optimized system is designed to achieve unprecedented accuracy in early detection while remaining fully scalable for population-level deployment.

The clinical validation research is supported by €3.5 million in highly competitive scientific funding (ERC + ERA4Health) and strong clinical partnerships.